Related Experiment Videos
[Chemo-radiotherapy for malignant brain tumors]
1Dept. of Neurosurgery, Kumamoto University Medical School.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|June 4, 2002
Summary
Radiotherapy plus chemotherapy improves survival for malignant gliomas and medulloblastoma. Combination chemotherapy shows promise for specific brain tumors, but neurotoxicity is a concern for primary CNS lymphoma.
Area of Science:
- Neuro-oncology
- Clinical trials
- Cancer treatment
Context:
- Malignant gliomas, medulloblastoma, primary CNS lymphoma, and intracranial germ cell tumors are aggressive brain cancers.
- Treatment advancements are crucial for improving patient outcomes and quality of life.
Purpose:
- To summarize the efficacy of combined radiotherapy and chemotherapy in treating various primary brain tumors.
- To highlight specific chemotherapy regimens and their impact on survival rates and treatment considerations.
Summary:
- For malignant gliomas, radiotherapy plus nitrosourea chemotherapy offers survival benefits in younger patients (<60 years), with combination chemotherapy (procarbazine/CCNU/vincristine) showing efficacy in anaplastic subtypes.
- Chemotherapy addition to radiotherapy improves survival in poor-risk medulloblastoma and may allow reduced radiation doses in good-risk cases.
- Combination chemotherapy with high-dose methotrexate (MTX) and radiotherapy improves survival for primary CNS lymphoma but poses neurotoxicity risks, especially in older adults.
- For intracranial germ cell tumors, combined chemotherapy and radiotherapy enhance survival in germinomas, while neoadjuvant therapy followed by surgery improves outcomes for nongerminomatous types.
Impact:
- Findings guide treatment strategies for brain tumors, emphasizing the role of combined modality therapy.
- Highlights the need for further research into combination chemotherapy regimens and managing treatment-related toxicities, particularly neurotoxicity.